University of Auckland part of a consortium awarded NZ8.8 million from Wellcome Trust (UK) for new drugs to improve bone marrow stem cell transplants in cancer patients

08 June 2012

The Wellcome Trust (UK) has approved a three-year, $NZ 8.8 million international grant to support a consortium of research groups in Australia and New Zealand to continue the development of a new class of immune-suppressive drugs to protect transplanted bone marrow stem cells against immune destruction.

The consortium comprising groups at the University of Auckland, the Peter MacCallum Cancer Centre and Monash University School of Biomedical Sciences in Melbourne, the Queensland Institute of Medical Research in Brisbane, and Medicines Development, is focused around their recent joint groundbreaking research into a protein called perforin, which is a potent toxin generated by killer cells of the immune system.

Professor Joe Trapani, Executive Director of Cancer Research at Peter Mac, who has studied perforin for well over 20 years, notes that while perforin is required for health, it can also have serious undesired effects, such as when the immune system attempts to rid the body of donated organ tissue or bone marrow following a transplant. In 2010, Professor Trapani, together with Professor James Whisstock’s team at Monash University, unravelled perforin’s molecular structure and confirmed that it destroys cells, by punching large holes in the cell surface.

Dr Julie Spicer, head of the project’s medicinal chemistry team on the project in the Auckland Cancer Society Research Centre (ACSRC) in the Faculty of Medical and Health Sciences at The University of Auckland, which is designing inhibitors of perforin, said “To gain an award from such a prestigious global charity is real recognition both of the quality of our research and the potential of this project to result in tangible benefits for cancer patients.”

Professor Bill Denny, Director of the ACSRC and a member of the research team, said: “This is a very exciting project for us, not only because of its novelty and its potential for cancer treatment, but also as another example that NZ science groups can participate at the highest international level.” He noted that early work on the project at the ACSRC was supported by Pre-Seed Accelerator funding from Auckland UniServices, the commercial arm of The University of Auckland.

Drs Spicer and Denny are also members of the Maurice Wilkins Centre (MWC), New Zealand’s national Centre of Excellence for drug development. Professor Rod Dunbar, Director of the MWC, said: "This announcement really represents New Zealand science at its best - a world-class team based right here, brought into a top-level international project because of their particular skills, to discover new medicines that will help patients world-wide."

The Dean of the Faculty of Medical and Health Sciences at The University of Auckland, Professor John Fraser, who is an immunologist, said: “Winning this award is a major achievement and reflects the very strong science that underpins the clever idea of perforin as a target for immune suppressive therapies. We are very proud that the ACSRC led by Professor Denny is an integral part of this international team.”

The Chief Executive of the Auckland Cancer Society, Mr John Loof, said "The New Zealand research community is to be congratulated for its part in securing this significant project. The work is vital if we are to make gains in this area. Yet again our scientists are recognised as being world leaders in their field".

With an understanding of its molecular structure in-hand and the Wellcome Trust funding, the research teams can now further develop these perforin blocking compounds for testing in humans. The consortium’s first generation of perforin inhibitors has already been shown, by Professor Geoff Hill’s group at the Queensland Institute of Medical Research, to prolong the survival of transplanted bone marrow stem cells in pre-clinical models. If the research team meets the scientific milestones set under the terms of the Wellcome Trust grant, initial clinical trials in human cancer patients will take place by 2016.

The perforin inhibitor project is funded under the Wellcome Trust’s Seeding Drug Discovery Initiative which aims to facilitate early-stage drug discovery.

– ends –

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk

For further information please contact: Dr Julie Spicer +64 9 923 6156, j.spicer@auckland.ac.nz

Professor Bill Denny +64 9 923 8144, b.denny@auckland.ac.nz

Judy Wilford Communications Department University of Auckland +64 9 373 7599 ext 83257 021 802 143 j.wilford@auckland.ac.nz